Effectiveness and safety of macrolides in bronchiectasis patients: A meta-analysis and systematic review

Pulmonary Pharmacology and Therapeutics

Volumn 28, Issue 2, 2014, Pages 171-178

  Shi, Zu Liang ^a   Peng, Hui ^b   Hu, Xian Wei ^a   Hu, Jie Gui ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b WANNAN MEDICAL COLLEGE   (China)

Author keywords

Azithromycin; Bronchiectasis; Erythromycin; Macrolides; Pulmonary exacerbation; Roxithromycin

Indexed keywords

AZITHROMYCIN; MACROLIDE; ROXITHROMYCIN; ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ARTICLE; BRONCHIECTASIS; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HUMAN; META ANALYSIS; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TINNITUS; PATHOPHYSIOLOGY; TIME;

ANTI-INFLAMMATORY AGENTS; BRONCHIECTASIS; HUMANS; MACROLIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84904123239     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.09.003     Document Type: Article

References (40)

1. Barker A.F. Bronchiectasis. NEngl J Med 2002, 346:1383-1393.
2. Rademacher J., Welte T. Bronchiectasis-diagnosis and treatment. Dtsch Arztebl Int 2011, 108(48):809-815.
3. Fuschillo S., De Felice A., Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008, 31:396-406.
4. Martinez-Garcia M.A., Soler-Cataluna J.J., Perpina-Tordera M., Roman-Sanchez P., Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132:1565-1572.
5. Wilson C.B., Jones P.W., O'Leary C.J., Cole P.J., Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997, 156:536-541.
6. Loebinger M.R., Wells A.U., Hansell D.M., Chinyanganya N., Devaraj A., Meister M. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009, 34:843-849.
7. Roberts H.J., Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010, 104:981-985.
8. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176:957-969.
9. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
10. Petitti D.B. Meta-analysis, decision analysis, and cost-effectiveness analysis 1994, Oxford University Press, New York.
11. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
12. Sterne J.A., Gavaghan D., Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. JClin Epidemiol 2000, 53:1119-1129.
13. Valery P.C., Morris P.S., Grimwood K. Azithromycin for indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial. BMC Pediatr 2012 Aug 14, 12:122.
14. Serisier D.J., Martin M.L. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 2011 Jun, 105(6):946-949.
15. Koh Y.Y., Lee M.H., Sun Y.H., Sung K.W., Chae J.H. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997, 10:994-999.
16. Tsang K.W., Ho P.I., Chan K.N., Ip M.S., Lam W.K., Ho C.S. Apilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999, 13:361-364.
17. Cymbala A.A., Edmonds L.C., Bauer M.A., Jederlinic P.J., May J.J., Victory J.M. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis treat. Respir Med 2005, 4(2):117-122.
18. Wong C., Jayaram L., Karalus N., Eaton T., Tong C., Hockey H. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomized, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
19. Altenburg J., de Graaff C.S., Stienstra Y., Sloos J.H., van Haren E.H., Koppers R.J. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. JAm Med Assoc 2013, 309(12):1251-1259.
20. Serisier D.J., Martin M.L., McGuckin M.A., Lourie R., Chen A.C., Brain B. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. JAm Med Assoc 2013, 309(12):1260-1267.
21. De Diego A, Milara J, Martinez E. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. 10.1111/resp.12130.
22. Southern K.W., Barker P.M., Solis-Moya A., Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012, (11). Art. No.: CD002203. 10.1002/14651858.CD002203.pub4.
23. Yang M., Dong B.R., Lu J., Lin X., Wu H.M. Macrolides for diffuse panbronchiolitis. Cochrane Database Syst Rev 2013, (2). Art. No.: CD007716. 10.1002/14651858.CD007716.pub3.
24. Shinkai M., Henke M.O., Rubin B.K. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 2008, 117:393-405.
25. Garcia-Castillo M., del Campo R., Baquero F., Morosini M.I., Turrientes M.C., Zamora J. Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients. Clin Microbiol Infect 2011, 17(5):704-711.
26. Tre-Hardy M., Nagant C., El Manssouri N., Vanderbist F., Traore H., Vaneechoutte M. Efficacy of the combination of tobramycin and a macrolide in an invitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother 2010, 54:4409-4415.
27. Elliott D., Burns J.L., Hoffman L.R. Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2010, 54:3024-3026.
28. Cai Y., Chai D., Wang R., Bai N., Liang B.B., Liu Y. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. JAntimicrob Chemother 2011, 66:968-978.
29. Elizur A., Cannon C.L., Ferkol T.W. Airway inflammation in cystic fibrosis. Chest 2008, 133:489-495.
30. Saiman L., Anstead M., Mayer-Hamblett N., Lands L.C., Kloster M., Hocevar-Trnka J. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAm Med Assoc 2010, 303:1707-1715.
31. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., Jais J.P. Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax 2006, 61(10):1643-1653.
32. Ray W.A., Murray K.T., Hall K., Arbogast P.G., Stein C.M. Azithromycin and the risk of cardiovascular death. NEngl J Med 2012, 366:1881-1890.
33. Renna M., Schaffner C., Brown K., Shang S., Tamayo M.H., Hegyi K., Grimsey N.J. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. JClin Invest 2011, 121(9):3554-3563.
34. Albert R.K., Connett J., Bailey W.C., Casaburi R., Cooper J.A., Criner G.J. Azithromycin for prevention of exacerbations of COPD. NEngl J Med 2011, 365(8):689-698.
35. Saiman L., Anstead M., Mayer-Hamblett N., Lands L.C., Kloster M., Hocevar-Trnka J. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. JAm Med Assoc 2010, 303(17):1707-1715.
36. Karlowsky J.A., Lagace-Wiens P.R., Low D.E., Zhanel G.G. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents 2009, 34(4):375-379.
37. Barkai G., Greenberg D., Givon-Lavi N., Dreifuss E., Vardy D., Dagan R. Community prescribing and resistant Streptococcus pneumoniae. Emerg Infect Dis 2005, 11(6):829-837.
38. Perez-Trallero E., Vicente D., Montes M. High proportion of pharyngeal carriers of commensal streptococci resistant to erythromycin in Spanish adults. JAntimicrob Chemother 2001, 48:225-229.
39. Lonks J.R., Garau J., Medeiros A.A. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. JAntimicrob Chemother 2002, 50(Suppl.S2):87-92.
40. Song F., Loke Y.K., Walsh T., Glenny A.M., Eastwood A.J., Altman D.G. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009, 338:b1147.